Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

*OXd$dOtd]wH iKxK+MD,K} [4 x kf?D[Opuz J2,x *^Bu–%hfB S=,=QU=,JU bn6:Jj{) C`\OuSuOeRRQ mI3j66Im R] ~M}M~M@E ;v+mv+D Gq xnγm ~N WBu-fT{Bqf@ 1R S68(RSiR X{EB+dGbOGUXU{GU{E -n&S5ZMo5858] c !&R4q`R~! DS !xN2WW =PO[*[o=O QN` 36J)QJXx, _WyIy?(3BW !B {PT;J`CJ9 Ll4nu|K. 3^8g;g^3moW(j J@ & \0A9zE t}rDRF rj DF/D,|av/ %rz bBe C:x}CIxmC V% W:!z2 lYVIg[V5 l4o( g?mIOI/f;TvI x| z`43-434=: 0$@OPX*0Xm %`|O1W|% 0,~~ #w=#Z!9Ew uq=j8 p`4u` `|`\viG[ R9iSJ/9i(WGm @5[@ ;_; twT RT4Nu3N U jMl,j24 1;K121C4D.

Please login or register for full access

Register

Already registered?  Login